Ampio updates phase III.

Ampio updates phase III, multicenter, double-blind STEP research of Ampion for knee osteoarthritis Ampio Pharmaceuticals, Inc . There have been two primary endpoints: 1. Efficacy in reducing discomfort, as measured by the WOMAC A discomfort subscore and 2. The WOMAC C Function subscore was examined as a secondary endpoint. Protection was examined in the basic safety dataset while efficacy was analyzed in the per-protocol population, in which patients met all access criteria and had no major protocol deviations.